Register for our free email digests:
Daiichi Sankyo Co., Ltd.
https://www.daiichisankyo.com/index.html
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Daiichi Sankyo Co., Ltd.
Genmab Accelerates Priority Candidates, Ends Enapotamab Vedotin Development
Denmark’s biotech Genmab has dropped the AXL targeted antibody-drug conjugate, enapotamab vedotin from early clinical development, and is focusing its resources on other therapeutic programs.
SynOx Seeks Solution For TGCT With Roche Antibody
The UK's Celleron has attracted a "blue chip suite of investors" to an Irish-domiciled spin-off based on the potential of Roche-developed emactuzumab for TGCT, a debilitating orphan disease that causes joint damage and has limited clinical options.
New Daiichi Structure Strengthens Oncology Focus
Japanese firm creates new US-based global organization that reaffirms strategic focus on oncology as main pillar of mid-term growth.
Japan Pharma Pandemic Impact: Win Some, Lose Some
As Japanese pharma companies report quarterly results, the multi-faceted impact of the ongoing coronavirus pandemic on business operations has become clearer. The good news is that it’s been limited so far and the situation has been generally improving.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- Generic Drugs
- OTC, Consumer
- Other Names / Subsidiaries
-
- Ambit Biosciences Corporation
- Asubio Pharmaceuticals, Inc.
- Daiichi Sankyo RD Novare Co., Ltd.
- Kitasato Daiichi Sankyo K.K.
- Im Co., Ltd., Luitpold Pharmaceuticals, Inc. (American Regent, Inc., PharmaForce, Inc.)
- Plexxikon Inc.
- Ranbaxy Laboratories Ltd.
- Roxro Pharma, Inc.
- Sankyo Pharma
- Suntory Pharmaceutical
- U3 Pharma AG
- Daiichi Sankyo India Pharma Private Limited
- Kitasato Daiichi Sankyo Vaccine Co., Ltd.
- Zenotech Laboratories Ltd.
- Daiichi Sankyo Vietnam Company Limited.